The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy
Open accessAbstract
The use of nanotechnology for drug delivery has shown great promise for improving cancer treatment. However, potential toxicity, hazardous environmental effects, issues with large-scale production, and potential excessive costs are challenges that confront their further clinical applications. Here, we describe a nanovector made from ginger-derived lipids that can serve as a delivery platform for the therapeutic agent doxorubicin (Dox) to treat colon cancer. We created nanoparticles from ginger and reassembled their lipids into ginger-derived nanovectors (GDNVs). A subsequent characterization showed that GDNVs were efficiently taken up by colon cancer cells. Viability and apoptosis assays and electric cell-substrate impedance-sensing technology revealed that GDNVs exhibited excellent biocompatibility up to 200 μmol/l; by contrast, cationic liposomes at the same concentrations decreased cell proliferation and increased apoptosis. GDNVs were capable of loading Dox with high efficiency and showed a better pH-dependent drug-release profile than commercially available liposomal-Dox. Modified GDNVs conjugated with the targeting ligand folic acid mediated targeted delivery of Dox to Colon-26 tumors in vivo and enhanced the chemotherapeutic inhibition of tumor growth compared with free drug. Current experiments explore the feasibility of producing nature-derived nanoparticles that are effective as a treatment vehicle while potentially attenuating the issues related to traditional synthetic nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Endophilin marks and controls a clathrin-independent endocytic pathway
Boucrot, E., Ferreira, A. P. A., Almeida-Souza, L., Debard, S., Vallis, Y., Howard, G., Bertot, L., Sauvonnet, N., & McMahon, H. T. (2015) · Nature · doi:10.1038/nature14067 · Cited by 542
pH-sensitive poly (histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery
Wu, H., Zhu, L., & Torchilin, V. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.072 · Cited by 355
Plant derived edible nanoparticles as a new therapeutic approach against diseases
Zhang, M., Viennois, E., Xu, C., & Merlin, D. (2016) · Tissue Barriers · doi:10.1080/21688370.2015.1134415 · Cited by 311
Self-citationZhuang, X., Teng, Y., Samykutty, A., Mu, J., Deng, Z., Zhang, L., Cao, P., Rong, Y., Yan, J., Miller, D., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2015.188 · Cited by 294
Cited by
Plant Exosome-like Nanovesicles: Emerging Therapeutics and Drug Delivery Nanoplatforms
Dad, H. A., Gu, T.-W., Zhu, A.-Q., Huang, L.-Q., & Peng, L.-H. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.030 · Cited by 745
Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
Cao, M., Yan, H., Han, X., Weng, L., Wei, Q., Sun, X., Lu, W., Wei, Q., Ye, J., Cai, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0817-4 · Cited by 552
Hybrid exosomes, exosome-like nanovesicles and engineered exosomes for therapeutic applications
Mondal, J., Pillarisetti, S., Junnuthula, V., Saha, M., Hwang, S. R., Park, I.-K., & Lee, Y.-K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.027 · Cited by 416
Plant-derived exosome-like nanoparticles and their therapeutic activities
Kim, J., Li, S., Zhang, S., & Wang, J. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.05.006 · Cited by 396
Lian, M. Q., Chng, W. H., Liang, J., Yeo, H. Q., Lee, C. K., Belaid, M., Tollemeto, M., Wacker, M. G., Czarny, B., & Pastorin, G. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12283 · Cited by 388
Metadata
- Authors
- Zhang, M., Xiao, B., Wang, H., Han, M. K., Zhang, Z., Viennois, E., Xu, C., & Merlin, D.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 24
- Issue
- 10
- Pages
- 1783-1796
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2486594993
- Cited by
- 456
- References
- 6
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.